Journal
ESMO OPEN
Volume 6, Issue 1, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.esmoop.2020.100044
Keywords
immunotherapy; immune checkpoints; second primary cancer; second malignant neoplasia
Categories
Funding
- LYRICAN [INCADGOS-INSERM 12563]
- NetSARC (INCA DGOS)
- TMRG (INCA DGOS)
- InterSARC (INCA)
- DEvweCAN [ANR-10-LABX-0061]
- PIA Institut Convergence Francois Rabelais PLAsCAN [17-CONV-0002]
- RHU4 DEPGYN [ANR-18-RHUS-0009]
- EURACAN [EC 739521]
- Association DAM
- la Fondation ARC
- Infosarcome
- Ligue de L'Ain Contre le Cancer
- La Ligue Contre le Cancer
Ask authors/readers for more resources
The use of ICIs for FPC appears to reduce the risk of developing SPC, while patients receiving CC or no ICIs/CC treatment for FPC have a higher incidence of SPC. Treatment with ICIs and/or CC for FPC is associated with a decreased risk of SPC in multivariate analysis.
Background: Second primary cancers (SPCs) are diagnosed in over 5% of patients after a first primary cancer (FPC). We explore here the impact of immune checkpoint inhibitors (ICIs) given for an FPC on the risk of SPC in different age groups, cancer types and treatments. Patients and methods: The files of the 46 829 patients diagnosed with an FPC in the Centre Leon Berard from 2013 to 2018 were analyzed. Structured data were extracted and electronic patient records were screened using a natural language processing tool, with validation using manual screening of 2818 files of patients. Univariate and multivariate analyses of the incidence of SPC according to patient characteristics and treatment were conducted. Results: Among the 46 829 patients, 1830 (3.9%) had a diagnosis of SPC with a median interval of 11.1 months (range 078 months); 18 128 (38.7%) received cytotoxic chemotherapy (CC) and 1163 (2.5%) received ICIs for the treatment of the FPC in this period. SPCs were observed in 7/1163 (0.6%) patients who had received ICIs for their FPC versus 437/16 997 (2.6%) patients receiving CC and no ICIs for the FPC versus 1386/28 669 (4.8%) for patients receiving neither CC nor ICIs for the FPC. This reduction was observed at all ages and for all histotypes analyzed. Treatment with ICIs and/or CC for the FPC are associated with a reduced risk of SPC in multivariate analysis. Conclusion: Immunotherapy with ICIs alone and in combination with CC was found to be associated with a reduced incidence of SPC for all ages and cancer types.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available